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Abstract
Background: Peroxisomes execute diverse and vital functions in virtually every eukaryote. New
peroxisomes form by budding from pre-existing organelles or de novo by vesiculation of the ER. It
has been suggested that ADP-ribosylation factors and COPI coatomer complexes are involved in
these processes.
Results: Here we show that all viable Saccharomyces cerevisiae strains deficient in one of the small
GTPases which have an important role in the regulation of vesicular transport contain functional
peroxisomes, and that the number of these organelles in oleate-grown cells is significantly
upregulated in the arf1 and arf3 null strains compared to the wild-type strain. In addition, we
provide evidence that a portion of endogenous Arf6, the mammalian orthologue of yeast Arf3, is
associated with the cytoplasmic face of rat liver peroxisomes. Despite this, ablation of Arf6 did
neither influence the regulation of peroxisome abundance nor affect the localization of peroxisomal
proteins in cultured fetal hepatocytes. However, co-overexpression of wild-type, GTP hydrolysis-
defective or (dominant-negative) GTP binding-defective forms of Arf1 and Arf6 caused
mislocalization of newly-synthesized peroxisomal proteins and resulted in an alteration of
peroxisome morphology.
Conclusion: These observations suggest that Arf6 is a key player in mammalian peroxisome
biogenesis. In addition, they also lend strong support to and extend the concept that specific Arf
isoform pairs may act in tandem to regulate exclusive trafficking pathways.
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Background
Peroxisomes are a diverse group of organelles which
accommodate many activities related to lipid metabo-
lism. In mammals, these organelles harbor a number of
essential metabolic functions including ether phospholi-
pid biosynthesis, fatty acid α – and β-oxidation, and gly-
oxylate detoxification [1]. The size, number and enzyme
content of peroxisomes can be affected by various envi-
ronmental, metabolic, and developmental factors [2-4].
Peroxisomes are thought to arise de novo from the endo-
plasmic reticulum (ER) [5-8] or multiply by fission of pre-
existing peroxisomes [3,9,10]. The relative contribution of
both pathways to the total number of peroxisomes in
wild-type cells is not yet clear [7,10,11], and the molecular
mechanisms governing these processes are only beginning
to be unraveled [12].
Studies in different model systems have demonstrated
that the Pex11p family of peroxisomal membrane pro-
teins (PMPs), a select set of dynamin-related proteins
(DRPs), and Fis1 and Mff – two putative adaptors for
DRPs – coordinately control the shape, size and number
of peroxisomes in a cell [3,11,13-15]. The Pex11 proteins
are supposed to be involved in the elongation and tubula-
tion of pre-existing peroxisomes, whereas the DRPs, Fis1,
and Mff are thought to catalyze the final fission event
[3,11,15]. It has been put forward also that ADP-ribosyla-
tion factors and coatomer proteins are involved in the bio-
synthetic process of the peroxisomal membrane [16].
Arguments in favor of this hypothesis are the observations
that (i) Arf1, Arf6, and COPI coatomer proteins can bind
to highly purified rat liver peroxisomes [17-19], (ii)
expression of a temperature-sensitive ε-COP subunit in
CHO cells at non-permissive temperature exhibited a dra-
matic change in peroxisome morphology [17], and (iii)
the S. cerevisiae orthologues of mammalian Arf1 (ScArf1)
and Arf6 (ScArf3) regulate peroxisome division up and
down, respectively [19]. Also, peroxisomal Arf/COPI
might be involved in the retrieval of cargo from peroxi-
somes back to the ER [12,16,20]. The observation that a
dominant-negative mutant of Arf1 inhibits the transport
pathway of tomato bushy stunt virus 33 kDa replication
protein from peroxisomes to the ER in Nicotiana tabacum
cells supports this hypothesis [21].
Arf1 and Arf6 are – together with Sar1 – the most compre-
hensively studied proteins of the ADP-ribosylation factor
(ARF) family [22]. Members of this group of small
GTPases are believed to control vesicular trafficking and
organelle structure by recruiting coat proteins, to function
as regulators of phospholipid metabolism, and to modu-
late cytoskeletal organization [23,24]. Arf1 has been
shown to function in the GTP-dependent recruitment of
COPI coatomer to budding transport vesicles that move
from the Golgi to the ER [25]. In addition, it has been
shown that ARF1-GTP regulates the recruitment of clath-
rin to late Golgi and endosome compartments through
binding with heterotetrameric adaptor protein complexes
as well as monomeric Golgi-localized γ-ear-containing
ARF-binding proteins [26]. Arf6, a protein predominantly
associated with the plasma membrane, is thought to reg-
ulate endosomal membrane delivery and traffic, mem-
brane raft trafficking, membrane recycling during
phagocytosis, and actin remodeling at the cell periphery
[23,24]. In this study, we dissect the potential role of
small GTPases, and especially of Arf6, in peroxisome bio-
genesis.
Results
Yeast cells deficient in Arf1 or Arf3 exhibit a pronounced 
increase in peroxisome number on oleate compared to 
wild-type cells
In view of a continuously increasing number of studies
reporting that the ER may provide peroxisomes with lip-
ids and some membrane proteins in the form of a preper-
oxisomal structure [10,27], we investigated whether or
not yeast strains deficient in one of the small GTPases that
function as a molecular switch in protein trafficking con-
tained functional peroxisomes. As such, all viable null
strains of the Rab and the Sar1/Arf families [28] (see
Methods for details) were tested for their ability to con-
sume oleate as a sole carbon source, a growth condition
requiring functional peroxisomes [29]. A wild-type strain
and a strain lacking Pex5p – the import receptor for per-
oxisomal matrix proteins containing a C-terminal peroxi-
somal targeting signal – were included as appropriate
controls, and oleate consumption was scored by halo for-
mation. None of the yeast strains deficient in one of the
small GTPases displayed significant changes in halo for-
mation compared to the wild-type strain (the results of
four representative strains are shown in Figure 1A). This
observation indicates that the corresponding GTPases are
not essential for peroxisome biogenesis in yeast. This con-
clusion is in line with our observations that none of these
strains displayed a detectable peroxisomal sorting defect
for the peroxisomal matrix protein marker EGFP-PTS1
(Figure 1B) or the peroxisomal membrane protein marker
Pex11p-EGFP (data not shown). Interestingly, the average
number of peroxisomes in oleate-grown cells was sub-
stantially increased in the Δarf1 and Δarf3 strains com-
pared to the wild-type strain (Figure 1C). To determine
whether or not these changes were significant, the values
obtained for the wild-type and Arf-null strains were ana-
lyzed more thoroughly. A one-way ANOVA showed sig-
nificant differences among the groups (p-value = 0.0001).
A subanalysis by the Tukey-Kramer multiple comparisons
procedure revealed that the peroxisome number in oleate-
grown Δarf1 and Δarf3 yeast cells did indeed significantlyBMC Cell Biology 2009, 10:58 http://www.biomedcentral.com/1471-2121/10/58
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Phenotypic analysis of various S. cerevisiae (deletion) strains Figure 1
Phenotypic analysis of various S. cerevisiae (deletion) strains. Serial dilutions of wild-type (WT) yeast cells (strain 
BY4741) and yeast cells deficient in Pex5p (Δpex5), Ypt8 (Δypt8), Arf1 (Δarf1), Arf2 (Δarf2), or Arf3 (Δarf3) expressing EGFP-
PTS1 were spotted onto plates with oleate as a sole carbon source. (A) The plates were subsequently incubated at 30°C for 
seven days, and oleate consumption was scored by halo formation. (B) Two days later, the subcellular distribution pattern of 
EGFP-PTS1 was visualized by fluorescence microscopy. The scale bar represents 5 μm. (C) The number of peroxisomes per 
cell was counted in randomly selected cells. The mean number of peroxisomes per cell is indicated by an asterisk. At least 100 
glucose-grown and 400 oleate-grown cells were scored.
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differ from that in oleate-grown wild-type cells (both p-
values < 0.0001). By contrast, there was no significant
pairwise difference between the peroxisome numbers in
oleate-grown Δarf2 and wild-type cells (p-value = 0.8733).
Summarized, these observations indicate that, at least
under certain growth conditions, Arf1 and Arf3 may be
involved in the regulation of peroxisome number in S. cer-
evisiae. Interestingly, the construction and analysis of a
double Δarf1Δarf3 deletion mutant revealed a cumulative
effect of each individual deletion when the cells were
grown on oleate (see Additional file 1).
Copurification of Arf proteins with rat liver peroxisomes
In order to investigate whether or not any endogenous Arf
proteins are associated with mammalian peroxisomes, we
probed rat liver subcellular fractions with 1D9, a mouse
monoclonal antibody that binds to a linear epitope found
in Arf proteins but not in other GTP-binding proteins
[30]. These experiments revealed the presence of a weak
but detectable 21 kDa 1D9-immunoreactive band in the
purified peroxisomal fraction (Figure 2A). By performing
membrane floatation experiments and employing Arf-
specific antibodies, we could show that this protein was
membrane-associated and most likely Arf6 (Figure 2B).
Consistent with this identification is the observation that
antibodies towards Arf1, Arf2, Arf3, and/or Arf4, but not
Arf6, did not yield a signal above background (data not
shown). Note that the anti-Arf6 antibody employed in
this study does not cross-react with Arf1, Arf3, or Arf4 (see
Additional file 2, panels B and C), and is only yielding a
detectable signal for Arf5 when this protein is expressed in
the high-nanogram to low-microgram range (see Addi-
tional file 2, panels B and C). Arf2 was not included in
these experiments, as this protein – which is absent in
humans – is 96% identical (at the amino acid level) to
Arf1 (see Additional file 2, panel A). The results obtained
with the anti-Arf5 antibody were not conclusive. That is, a
very weak signal could be observed, but only after very
long exposure times (data not shown). However, as the
epitope recognized by the monoclonal antibody directed
against Arf5 is unknown, we can not exclude the possibil-
ity of some cross-reactivity with Arf6. Finally, as (i) subcel-
lular fractionation cannot exclude with absolute certainty
that a particular protein is located in a contaminating
organelle that co-purifies with the organelle under study,
and (ii) the peroxisomal fractions employed also con-
tained small amounts of glutamate dehydrogenase (mito-
chondria), BiP/GRP78 (endoplasmic reticulum), and
pan-cadherin (plasma membrane) (Figure 2A), we sub-
jected peroxisomal fractions with different degrees of
purity to immunoelectron microscopy. These experiments
established that the anti-Arf 1D9 (Figures 3, 4A, and 5)
and anti-Arf6 (Figure 4B) antibodies specifically recog-
nized a protein on the outer aspect of the peroxisomal
membrane, and not on the membrane of a contaminating
organelle.
Arf6 is not essential for peroxisome biogenesis in mouse 
hepatocytes
In order to investigate the potential role of Arf6 in perox-
isome biogenesis, we examined the number of peroxi-
somes, peroxisomal morphology, and the localization of
peroxisomal membrane and matrix proteins in Arf6-/- fetal
hepatocytes [31]. As it is well-known that peroxisomes in
cultured hepatoma cells may exhibit distinct alterations of
shape, size, and distribution dependent on culture condi-
tions (including cell density, duration in culture, and the
presence of specific growth factors) [32], we analyzed
high, middle and low density hepatocyte populations
from wild-type and knockout animals side-by-side. Prob-
ing these cells with antibodies raised against the peroxiso-
mal membrane protein Pex14p (Figure 6C), the PTS1
protein catalase (see Additional file 3), the peroxisomal
membrane protein PMP70 (data not shown) or the PTS2
protein thiolase (data not shown) showed that ablation of
Arf6 did not visibly alter the localization of peroxisomal
proteins in cultured fetal hepatocytes from both control
and clofibrate-treated pregnant mice. Clofibrate is a
hypolipidemic drug known to induce peroxisome prolif-
eration in rodent liver (Figure 6A). In addition, no evi-
dence could be found for an altered number (Figure 6B)
or spatial distribution (see Figure 6C and Additional file
3) of peroxisomes. These findings may be surprising in
light of our observations that the number of peroxisomes
is altered in S. cerevisiae cells deficient in Arf3 (Figure 1C),
the yeast orthologue of mammalian Arf6 [33]. We suggest
that a functional redundancy of different Arf proteins may
protect peroxisome biogenesis in mammals. In this con-
text it is interesting to point out that every combination of
double – but not single – knockdowns of Arf1, Arf3, Arf4
and Arf5 yielded a distinct pattern of defects in secretory
and endocytic traffic in HeLa cells [34].
Co-overexpression of Arf1 and Arf6 variants impairs 
peroxisomal protein import in mammalian cells
As a previous study has shown that exogenously added
Arf1 can bind to highly purified rat liver peroxisomes [19],
we investigated whether or not overexpression of wild-
type, GTP hydrolysis-defective or (dominant-negative)
GTP binding-defective variants of Arf1 (Arf1wt, Arf1Q71L
[35], and Arf1T31N [35], respectively) and Arf6 (Arf6wt,
Arf6Q67L [36], and Arf6T27N [37], respectively), individu-
ally or in pairwise combinations, affected peroxisomal
protein import in mammalian cells. These experiments
demonstrated that overexpression of individual Arf vari-
ants had no effect on the localization of EGFP-PTS1, a per-BMC Cell Biology 2009, 10:58 http://www.biomedcentral.com/1471-2121/10/58
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Arf6 copurifies with the peroxisomal membrane fractions Figure 2
Arf6 copurifies with the peroxisomal membrane fractions. (A) Rat liver homogenates were fractionated into a postnu-
clear (E), a nuclear (N), a heavy mitochondrial (M), a light mitochondrial (L), a microsomal (P), and a cytosolic (S) fraction. A 
peroxisome-enriched fraction (PO) was obtained by centrifugation of the L-fraction on a Nycodenz step gradient (see Meth-
ods). Equal amounts of protein were subjected to SDS-PAGE, transferred to nitrocellulose, and immunoblotted with antibod-
ies raised against the nuclear pore complex protein p62 (Nup62), mitochondrial glutamate dehydrogenase (GDH), lysosomal-
associated membrane protein 2 (LAMP2), the ER-resident chaperone immunoglobulin binding protein (BiP/GRP78), the micro-
tubule-binding peripheral Golgi membrane 58 kDa protein (Golgi 58 K), the plasma membrane protein pan-cadherin (Pan-cad-
herin), the peroxisomal membrane protein Pex13p (Pex13p), peroxisomal biogenesis factor 19 (Pex19p), or a linear epitope 
found in Arf proteins (1D9). Note that the majority of Golgi 58 K is soluble after fractionation, and that Pex19p is a predomi-
nantly cytosolic, partly peroxisomal protein. (B) Six milligrams of total protein from the peroxisomal fraction was processed 
for floatation centrifugation in an alkaline sucrose gradient (see Methods). The fractions were collected from the bottom, proc-
essed for SDS-PAGE, transferred to a nitrocellulose membrane, and stained for total protein with Ponceau S (upper panel). A 
select set of fractions was immunoblotted with anti-Arf 1D9 or antibodies against Arf6 or peroxisomal matrix (catalase), core 
(urate oxidase), or membrane proteins (Pex3p, PMP70) (lower panels). The density (in g/ml) of the gradient fractions and the 
migration of the molecular mass markers (their masses expressed in kDa) are indicated.
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oxisomal matrix protein reporter (Figure 7A). However,
when Arf1 and Arf6 variants were simultaneously
expressed, all combinations yielded a mislocalization of
the reporter protein to various degrees (Figure 7A). Inter-
estingly, co-expression of the GDP-bound dominant-neg-
ative mutants Arf6T27N and Arf1T31N resulted in a partial to
complete cytosolic localization of EGFP-PTS1 in approxi-
mately 80% of the cells (Figures 7A and 7B (left column
and upper row)). Similar findings were observed for
HsPMP34-Myc-His, a PMP reporter protein (Figure 7B,
middle column). This observation indicates that the mis-
localization of EGFP-PTS1 is most likely the indirect result
of a peroxisomal membrane protein import deficiency. At
first sight, this hypothesis seems to be at odds with the
observation that a simultaneous expression of Arf6T27N
and Arf1T31N did not have a visible effect on the subcellu-
lar localization of endogenous Pex14p (Figure 7, left col-
umn). However, as (i) the half-life of peroxisomes in
cultured mammalian cells is approximately two days, and
(ii) the turnover rate of Pex14p is rather low [38], the
Pex14p signals observed in Figure 7B most likely represent
pre-existing Pex14p molecules which were already local-
ized to peroxisomes before Arf6T27N and Arf1T31N were co-
overexpressed. Interestingly, upon closer inspection, we
found that the staining pattern of Pex14p was slightly
changed in at least some cells co-overexpressing Arf6T27N
and Arf1T31N (see Additional file 4, compare the Pex14p
signals in non- or single transfected cells with those in
double-transfected cells). Indeed, a diffuse 'background'
staining could be observed (most likely representing the
pool of newly-synthesized Pex14p), and – upon a drastic
enlargement of the images – it became also clear that the
appearance of the Pex14p-immunoreactive particles was
affected (see Additional file 5). The precise nature and
mechanism of these changes remain to be determined.
Importantly, Arf3, Arf4, and Arf5 could not substitute for
Arf1 in these assays (data not shown). In addition, co-
expression of the GDP-bound dominant-negative variants
of Arf1 and Arf6 did not interfere with the sorting of
HsLK2-Myc-His, a mitochondrial reporter protein (Figure
7B, right column).
Discussion
In many instances, the formation of membrane-delimited
compartments from pre-existing organelles is regulated by
small GTPases of the Rab and Arf family [22,23,39,40]. A
growing amount of evidence suggests that monomeric
GTP-binding proteins may also play a role in peroxisome
biogenesis. For example, mass spectrometry-based quan-
titative proteomic profiling studies have shown that in
yeast Rho1 is recruited to peroxisomes upon their induc-
tion by oleate, and it has been suggested that this protein
regulates the assembly state of actin on the peroxisome
membrane, thereby controlling peroxisome membrane
dynamics and biogenesis [41]. Recently, it has also been
shown that MYA2, an isoform of Arabidopsis thaliana
myosin XI, is targeted to peroxisomes through an interac-
tion with AtRab2CA [42]. Furthermore, mammalian Arf1
and Arf6 have been shown to bind to isolated rat liver per-
oxisomes, and ScArf1 and ScArf3, the yeast orthologues of
these proteins, have been implicated in the control of per-
oxisome proliferation [19]. A similar function has been
suggested for Trypanosoma brucei Arf1, a protein which
shares characteristics with both Arf1 and Arf6 and has a
vital role in the maintenance of the endocytic pathway
[43]. Interestingly, no Arf proteins have been identified in
proteome studies of yeast and mammalian peroxisomes
[41,44-50]. A possible explanation might be that the rela-
tive abundance of these proteins in the analyzed samples
is extremely low.
In this study, we initially investigated whether or not yeast
strains deficient in Arf1, Arf2, Arf3, Arl1, Cin4, Vps21,
Ypt6, Ypt7, Ypt10, Ypt11, Ypt31, Ypt32, Ypt52 or Ypt53
Electron microscopic localization of 1D9-immunoreactive  proteins in prestained epoxy-embedded preparations of rat  liver peroxisomes Figure 3
Electron microscopic localization of 1D9-immunore-
active proteins in prestained epoxy-embedded prep-
arations of rat liver peroxisomes. Nycodenz-purified rat 
liver peroxisomes were processed for pre-embedding double 
immunoelectron microscopy (see Methods). Rabbit anti-
PMP70 (α-PMP70) and mouse monoclonal 1D9 antibodies 
were used as primary antibodies, and 12 nm gold-conjugated 
anti-rabbit IgG (α-12 nm gold) and 18 nm gold-conjugated 
anti-mouse IgG (α-18 nm gold) as labels. The primary anti-
bodies were omitted from samples used as negative control 
(left column). The images were obtained from 75 nm (upper 
panels) and 300 nm thick (lower panels) sections. The origi-
nal magnification was 27,800-fold; the scale bar represents 
500 nm.
75 nm
300 nm
D-18 nm gold
D-12 nm gold
1D9 / D-18 nm gold
D-PMP70 / D-12 nm goldBMC Cell Biology 2009, 10:58 http://www.biomedcentral.com/1471-2121/10/58
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were capable of growing on oleate as a sole carbon source
and/or displayed a peroxisomal protein sorting defect.
The results of these experiments demonstrated that all
these strains, which embody every viable yeast deletion
mutant of the Rab and Sar1/Arf subfamilies of small
GTPases, contain functional peroxisomes. Interestingly,
the average number of peroxisomes in oleate-grown cells
was significantly upregulated in the Δarf1  and  Δarf3
strains compared to the wild-type strain, and this pheno-
type was even more pronounced in the double Δarf1Δarf3
deletion mutant. This observation indicates that ScArf1
and ScArf3 dampen peroxisome proliferation, either
directly or indirectly. Although this result confirms previ-
ous observations that ScArf1 and ScArf3 are implicated in
the control of peroxisome proliferation [19], it is not con-
sistent with the authors' conclusion that ScArf1 is required
for the oleate-induced peroxisome proliferation in S. cere-
visiae. The reasons for the discrepancy between our results
and the results previously presented might be several. For
example, while we were making use of an Arf1 deletion
mutant, Lay et al. [19] utilized an Arf1 temperature-sensi-
tive mutant in an Δarf2  background. Also, while these
authors analyzed the peroxisome number per cell after 6
hours of growth on oleate, we analyzed the cells after 5 or
9 days of growth on oleate. Note that after transfer of the
cells to oleate-containing medium, the number of peroxi-
somes per cell continuously increased as a function of
time for at least 14 days, in the Δarf1 and Δarf3 strains
compared to the wild-type strain (data not shown). At this
point, it is not clear how Arf1 and Arf3 suppress oleate-
induced peroxisome proliferation in S. cerevisiae. One
possibility might be that these proteins are involved in the
generation of peroxisome-derived vesicles, which trans-
port ER-derived factors from peroxisomes back to the ER
[7,8,12,16] or deliver metabolites, lipids, or (mistargeted)
proteins to mitochondria [51]. Disturbances in such path-
ways would result in an increase in peroxisome number.
We next investigated whether or not endogenous Arf pro-
teins were associated with the membrane of rat liver per-
oxisomes. In a first series of experiments, we obtained
evidence that 1D9, a mouse monoclonal antibody with
specificity for mammalian Arf1, Arf2, Arf3, Arf5, Arf6, and
– to a lesser extent – Arf4 [30], recognized a 21 kDa band
in highly purified peroxisomal membrane preparations.
We could show that this 21 kDa protein was associated
with the outside face of the peroxisomal membrane (as
determined by immuno-electron microscopy), and iden-
tify this protein as Arf6 (as determined with Arf-specific
antibodies). This protein, which is considered to be the
mammalian orthologue of yeast Arf3, has been reported
to act in a wide range of processes, including endocytosis,
cytokinesis, phagocytosis, and the organization of the
actin cytoskeleton [22]. Our observation that endogenous
Arf6 is also associated with peroxisomes may seem sur-
prising given that the subcellular localization of this pro-
tein has already been documented in several reports
[30,52-54]. However, as (hepatic) peroxisomes occupy
less than 2% of the cell volume [55], a partial (and tran-
sient) association of Arf6 with these organelles may have
been easily missed. Also, as the strength of the signal and
its detection depend heavily on the amount of protein
and may be easily masked by stronger signals, the meth-
ods employed might not be sensitive enough. No evi-
dence could be obtained for the association of any other
endogenous Arf protein with the peroxisomal membrane.
However, these results should be considered with caution
as such proteins may dissociate during the purification
Electron microscopic localization of 1D9- and anti-Arf6- immunoreactive proteins in Nycodenz-purified peroxisomal  fractions immobilized on poly-L-lysine-coated grids Figure 4
Electron microscopic localization of 1D9- and anti-
Arf6-immunoreactive proteins in Nycodenz-purified 
peroxisomal fractions immobilized on poly-L-lysine-
coated grids. (A) Prestained organellar fraction (see Meth-
ods). Rabbit anti-PMP70 (α-PMP70) and mouse monoclonal 
1D9 were used as primary antibodies, and 12 nm gold-conju-
gated anti-rabbit IgG (α-12 nm gold) and 18 nm gold-conju-
gated anti-mouse IgG (α-18 nm gold) as labels. (B) 
Poststained organellar fraction (see Methods). Rabbit anti-
PMP70 (α-PMP70) and mouse anti-Arf6 (α-Arf6) were used 
as primary antibodies, and the same secondary antibodies 
were used as in panel A. Negative controls were included in 
parallel in which the primary antibodies were omitted (left 
panels). The original magnification was 60,000-fold (upper 
panels), 27,800-fold (lower left panel), or 46,460 fold (lower 
right panel); the scale bar represents 500 nm.
prestaining
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D-PMP70 / D-12 nm gold
poststaining
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procedure and be present on the peroxisomal membrane
in concentrations below the detection limits of the
employed Arf-specific antibodies.
To study the function of Arf6 in peroxisome biogenesis,
we first examined the number of peroxisomes, peroxiso-
mal morphology, and the location of (newly-synthesized)
peroxisomal membrane and matrix proteins in (i) Ptk2
cells transiently overexpressing either wild-type Arf6 or a
mutant defective in GTP-binding (Arf6T27N) or GTP-
hydrolysis (Arf6Q67L) and (ii) Arf6-/- fetal mouse hepato-
cytes [31]. Neither the overexpression of Arf6 variants nor
the absence of Arf6 resulted in a detectable peroxisomal
phenotype. Together, these observations suggest that per-
oxisome-bound Arf6 alone is not essential for peroxisome
biogenesis in mammalian cells. The lack of a phenotypic
defect is most probably the result of functional redun-
dancy among individual Arf proteins [34], and since it has
been reported that exogenously added Arf1 can bind to
isolated rat liver peroxisomes [19], we decided to carry out
another series of experiments in which Arf6WT, Arf6T27N,
or Arf6Q67L were transiently co-overexpressed with either
wild-type Arf1 or a mutant defective in GDP-binding
(Arf1T31N,) or GTP-hydrolysis (Arf1Q71L). These experi-
ments showed that a combined overexpression of Arf1
and Arf6 variants resulted in a (partial) mislocalization of
newly-synthesized peroxisomal reporter proteins and an
altered peroxisome morphology. Importantly, the intrac-
ellular transport pathway of HsLK2-Myc-His, a human
mitochondrial multisubstrate lipid kinase [56], was not
disturbed. Interestingly, combinations with Arf1T31N and
Arf6T27N consistently displayed the strongest phenotypes.
Similar observations were observed in CHO and HepG2
cells (data not shown). These mutants are thought to
render endogenous Arf1 and Arf6 inactive, presumably by
sequestering a select set of guanine nucleotide exchange
factors [35,52]. Since a similar, but less drastic, phenotype
was observed when other Arf6 and Arf1 variants were
expressed, and Arf3, Arf4, and Arf5 could not substitute
for Arf1, it is unlikely that the (partial) mislocalization of
the peroxisomal reporter proteins is the result of indirect
changes in the level of activation of other Arf subtypes. In
addition, our observation that a similar phenotype was
obtained with all Arf1 and Arf6 variants also suggests the
necessity for a completion of the GDP/GTP cycle of these
proteins to achieve their potential function in peroxisome
biogenesis [[57], and references therein]. In summary,
these findings – which suggest that Arf1 and Arf6 act in
tandem to regulate a peroxisomal trafficking pathway –
lend strong support to and extend the hypothesis that the
cooperation of two Arf proteins at the same subcellular
location is a general feature of Arf signaling [34].
To date, only one group has studied the potential relation-
ship between ADP-ribosylation factors and peroxisome
formation in mammalian cells, and shown that exoge-
nously added Arf1 and Arf6 can bind to isolated rat liver
peroxisomes [17,19]. In this work, we have extended these
findings by showing that (i) also endogenous Arf6 associ-
ates with the cytoplasmic side of the peroxisomal mem-
brane, and (ii) a combined overexpression of Arf6 and
Arf1 variants selectively impairs peroxisomal protein
Organellar distribution of 1D9- and anti-PMP70-immunore- active proteins in enriched peroxisomal rat liver fractions Figure 5
Organellar distribution of 1D9- and anti-PMP70-
immunoreactive proteins in enriched peroxisomal 
rat liver fractions. Percoll-, Nycodenz- and Percoll/
Nycodenz-purified peroxisomal fractions were processed for 
pre-embedding double immunoelectron microscopy using 
anti-Arf 1D9 (18 nm gold grains) and anti-PMP70 (12 nm gold 
grains) antibodies (see legend to Figure 3). Epon-embedded 
fractions were quantitatively analyzed for the density of labe-
ling on organellar membranes. The results are expressed as 
relative specific labeling (R.S.L.) versus percentage of total 
cell organelles. R.S.L. is hereby defined as the percentage of 
total gold particles present on a particular organelle divided 
by the corresponding percentage of total organelles. R.S.L. 
values greater than one indicate enrichment of the labeling in 
that specific fraction. The combined total number of cell 
organelles (x-axis) and gold particles (y-axis) is indicated. 
Note that the purity of the peroxisomal Percoll, Nycodenz, 
and Percoll/Nycodenz fractions was 60%, 70%, and 77%, 
respectively. Abbreviations: PO, peroxisomes (vesicular 
structures labeled with anti-PMP70 antibodies); MT, mito-
chondria (double membrane-bound organelles with cristae); 
O, other vesicles (vesicular structures which could not be 
unambiguously identified as peroxisomes or mitochondria).
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import and alters peroxisome morphology. The molecular
mechanisms underlying these phenotypic alterations
remain to be clarified, since these Arf proteins do not
interact directly with any of the currently identified
human peroxins as tested with yeast- and bacterial two-
hybrid assays (data not shown). Nevertheless, based on
(i) a recent report showing that active Arf6 can recruit
ARNO – a soluble Arf1 GTPase-activating guanine nucle-
otide exchange factor – to the plasma membrane [58], (ii)
a growing body of evidence supporting the existence of
vesicular trafficking pathways between peroxisomes and
other subcellular compartments [8,51], and (iii) the
observation that Arf1 is involved in the transport pathway
of tomato bushy stunt virus 33 kDa replication protein
from peroxisomes to the ER in Nicotiana tabacum cells
[21], it is tempting to speculate that activated peroxisomal
Arf6 is involved in the formation of peroxisome-derived
vesicles by serving as an adaptor for the recruitment of not
yet identified guanine nucleotide exchange factor(s) to
sites at the peroxisomal membrane which in turn may
lead to Arf1 activation and cytosolic coat protein recruit-
ment. Depending on the functional redundancy among
the Arf proteins and the role of the peroxisome-derived
vesicles in different organisms, the inability of a cell to
form such vesicles may result in an increase in peroxisome
number or a block in the formation of new organelles.
Conclusion
In this study, we provide evidence that endogenous Arf6,
the mammalian orthologue of S. cerevisiae Arf3, can
tightly associate with the outside face of the peroxisomal
membrane. We also demonstrated that a combined over-
expression of Arf6 and Arf1 variants caused mislocaliza-
tion of newly-synthesized peroxisomal proteins and
resulted in an alteration of peroxisome morphology.
These observations suggest that Arf6 – albeit not essential
– is a key player in mammalian peroxisome biogenesis. In
addition, these findings extend the concept that specific
Arf isoform pairs may act in tandem to regulate exclusive
trafficking pathways. The precise mechanism by which
Arf6 functions in peroxisome biogenesis remains to be
determined.
Methods
Animals
Male Wistar rats (weighing 200–250 g), Swiss-Webster
mice, and New Zealand White rabbits were kept in a con-
stant light-dark cycle on a standard laboratory diet. The
rats were fasted 16 hours before sacrifice. Arf6+/- C57BL/6
mice were maintained in a pathogen-free facility as
described elsewhere [31]. To study the effect of a peroxi-
some proliferator on the numerical abundance, structure,
and protein import competence of peroxisomes in Arf6-/-
fetal hepatocytes, pregnant Arf6+/- mice were fed a diet
containing 0.3% (w/w) clofibrate beginning at day 6.5 of
gestation [59]. All animal experiments were approved by
the local institutional ethics committees.
Plasmids
Cloning vectors were obtained from Qiagen (pQE30),
Clontech (pEGFP-N1, pIRES2-EGFP) or Stratagene
(pCMV-Tag4A, B), and the oligonucleotides synthesized
for this study were from Eurogentec. PCR applications
were performed routinely using Pfx  DNA polymerase
(Invitrogen). Restriction enzymes were purchased from
TaKaRa. The Escherichia coli strain Top10F'  (Invitrogen)
was used for all DNA manipulations. Full-length cDNAs
coding for human (Homo sapiens, Hs) Arf1 (accession
number NM_001649), Arf3 (accession number
NM_001659), Arf4 (accession number NM_001660),
Arf5 (accession number NM_001662), and Arf6 (acces-
sion number NM_001663) were obtained from the
I.M.A.G.E. consortium (clones 3463523, 2967578,
6157009, 6720876, and 5212700, respectively) [60]. The
mammalian expression vectors coding for Bos Taurus (Bt)
Arf1WT-HA, HsArf1T31N-HA, or HsArf1Q71L-HA [61] were
obtained from Addgene (plasmids 10830, 10833, and
10832, respectively). The plasmids coding for HsArf6-HA,
HsArf6T27N-HA, or HsArf6Q67L-HA were kindly provided
by Dr. P. Chavrier (Institut Curie, Paris, France). The yeast
expression vector encoding EGFP-PTS1 (pJR233) was
kindly provided by Dr. A. Hartig (University of Vienna,
Austria). The mammalian expression plasmids pTW360
(coding for HsPMP34-Myc-His) and pSG005 (coding for
HsLK2-Myc-His) have been described elsewhere [56,62].
The bicistronic expression plasmids coding for EGFP-
PTS1 and non-tagged HsArf1T31N  (pEA42), HsArf6WT
(pEA38) or HsArf6Q67L  (pEA91) were constructed by
amplifying the corresponding cDNAs by PCR (Arf1 prim-
ers: 5'-gtttgagatctcatggggaacatcttcgcc-3' (HsArf1F1) and 5'-
caaaagtcgactcacttctggttccggagc-3' (HsArfR4); Arf6 primers:
5'-gtttgagatctgatggggaaggtgctatcc-3' (HsArf6f1) and 5'-
gtgtggtcgactcattaagatttgtagttagagg-3' (HsArf6r4)), and
cloning the Bgl II/Sal I-digested PCR products into the
multiple cloning site of pIRES2-EGFP-PTS1 (pMF891)
[63] digested with the same restriction enzymes. The bicis-
tronic plasmid coding for EGFP-PTS1 and non-tagged
HsArf6T27N (pEA43) was constructed by fusion PCR. In a
first PCR reaction, two PCR fragments (template: pEA38;
primers: 5'-ggactttcctacttggcag-3' (pIRES2-EGFP-f1) and
5'-ggattgtattcttgccggccgcgtcc-3' (HsArf6T27Nr1) (frag-
ment 1), 5'-ccggcaagaatacaatcctgtacaagttgaag-3'
(HsArf6T27Nf1) and HsArf6r4 (fragment 2)) were gener-
ated. These PCR fragments were fused and used as a tem-
plate in a second PCR reaction (primers: HsArf6f1,
HsArf6r4). After digestion with Bgl II and Sal I, the fusionBMC Cell Biology 2009, 10:58 http://www.biomedcentral.com/1471-2121/10/58
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fragment was subcloned into the Bgl  II/Sal  I-digested
pIRES2-EGFP-PTS1 vector. The mammalian expression
vectors coding for HsArf3-FLAG (pMF1599), HsArf4-
FLAG (pMF1598) or Arf5-FLAG (pMF1577) were con-
structed by transferring the Bam  HI/Bgl II-digested
(pMF1577, pMF1599) or Bgl II/Sal I-digested (pMF1598)
cDNA inserts from pEA51, pEA35, and pEA52 into the
Bam HI-digested pCMV-Tag4A (pMF1577), Bgl II/Sal I-
digested pCMV-Tag4B (pMF1598), or Bgl  II/Bam  HI-
digested pCMV-Tag4B (pMF1599) vectors. To generate
pMF214, a bacterial expression plasmid coding for (His)6-
HsPex3p(229–364) [64], the 403 bp Bam HI – Hind III frag-
ment of the PEX3 open reading frame was ligated into
Bam HI/Hind III-restricted pQE30. All essential constructs
were verified by DNA sequencing (Agowa).
Yeast strains
The haploid Saccharomyces cerevisiae strains BY4741 (gen-
otype: MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0; accession
number Y00000) and BY4742 (genotype: MATα ; his3Δ1;
leu2Δ0; lys2Δ0; ura3Δ0; accession number Y10000) as well
as the corresponding null mutants (open reading
frame::KanMX4) of arf1  (Y03890), arf2  (Y03835),  arf3
(Y01870 and Y11870), arl1  (Y03304),  cin4  (Y06744),
pex5  (Y03603),  vps21  (Y01865),  ypt6  (Y05171),  ypt7
(Y00575),  ypt10  (Y03404),  ypt11  (Y01140),  ypt31
(Y06583),  ypt32  (Y04576),  ypt52  (Y05085), and ypt53
(Y07232) were obtained from Euroscarf. Yeast cells were
transformed and selected as described [65]. In order to
construct the double arf1arf3 deletion strain, the single
arf1 (Y03890) and arf3 (Y11870) deletion strains were
crossed with each other. Diploids were selected on -lys -
met medium and checked by mating type PCR. The dip-
loids were sporulated and subjected to tetrad analysis.
Double deletion strains were selected on medium con-
taining Geneticin (2:2 segregation for growth on
Geneticin indicates that the two mutations are together)
and verified by PCR analysis. To assay yeast cells for
growth in the presence of oleate as a sole carbon source,
the cells were pelleted, washed, and resuspended in sterile
water to an optical density of 0.4 at 600 nm. Ten-fold
serial dilutions were spotted on oleic acid plates contain-
ing 0.1% (v/v) oleic acid, 0.4% (v/v) Tween-40, 0.1% (w/
v) yeast extract (Difco), 2% (w/v) agar, and synthetic
dropout medium [66].
Antibodies
The polyclonal antiserum against (His)6-HsPex3p(229–364)
was raised in New Zealand White rabbits as previously
described [67]. The mouse polyclonal antiserum against
bovine catalase and the rabbit polyclonal antisera against
HsPex13p, HsPex14p, HsPex19p, rat peroxisomal thio-
lase, and rat liver peroxisomal matrix proteins (ab-MF16;
used to detect catalase and urate oxidase on Western blot)
Arf6 is not essential for peroxisome biogenesis in fetal  mouse hepatocytes from control and clofibrate-treated preg- nant mice Figure 6
Arf6 is not essential for peroxisome biogenesis in 
fetal mouse hepatocytes from control and clofibrate-
treated pregnant mice. (A) Protein (25 μg), present in 
liver postnuclear supernatants from control (-CF) and clofi-
brate-treated (+CF) pregnant Arf6+/- mice (see Methods), was 
subjected to SDS-PAGE, transferred to PVDF, and immunob-
lotted with antibodies against cytochrome P450 4A (Cyt 
P450; a non-peroxisomal clofibrate-inducible enzyme), the L-
specific peroxisomal multifunctional protein (MFP1; a clofi-
brate-inducible enzyme), peroxisomal thiolase (thiol; a clofi-
brate-inducible enzyme), or catalase (cat; a peroxisomal 
enzyme not induced by clofibrate). The asterisk indicates the 
migration of a nonspecific, immunoreactive protein. (B, C) 
Primary hepatocytes from mouse embryos (13.5 days) of 
Arf6+/+ and Arf6-/- littermates from control and clofibrate-
treated pregnant Arf6+/- mice were isolated, seeded on colla-
gen-coated cover glasses, cultured for 12 hours, and proc-
essed for indirect immunofluorescence microscopy. (B) 
Representative pictures showing that ARF6 ablation does not 
alter the localization of Pex14p, a peroxisomal membrane 
protein. The scale bar represents 10 μm. (C) The number of 
peroxisomes (per cell section; n > 15) is not substantially 
altered in wild-type and Arf6-/- cells. The error bars indicate 
the standard deviation.
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are described elsewhere [63,64,68,69]. The 1-9E10.2
hybridoma cell line producing anti-Myc antibody [70]
was obtained from A.T.C.C. All other primary antibodies
were commercially obtained. This list includes (i) rabbit
polyclonal antibodies against Arf (Santa Cruz Biotechnol-
ogy, sc-9063), glutamate dehydrogenase (Rockland
Immunochemicals, 100–4158), PMP70 (Zymed Labora-
tories, 71–8300), HA (GeneTex, GTX29110), cytochrome
P450 4A (Affinity BioReagents, PA3-033), and LAMP2
(Sigma, L 0068), (ii) an affinity-purified goat polyclonal
antibody against Arf (Santa Cruz Biotechnology, sc-
7622), (iii) a rabbit monoclonal antibody against Arf1
(Abcam, ab32524, clone [EP442Y]), and (iv) mouse mon-
oclonal antibodies against Arf3 (BD Biosciences, 610785,
clone [41]), nucleoporin 60 (BD Biosciences, N43620),
Bip/GRP78 (BD Biosciences, G73320), pan-cadherin
(Sigma, C 1821), Golgi 58 K (Sigma, G 2404), Arf
(Abcam, ab2806, clone [1D9]), Arf5 (Abnova,
H00003428-M05, clone [1B4]), Arf6 (Santa Cruz Biotech-
nology, sc-7971, clone [3A-1]), and HA (Roche,
11583816001, clone [12CA5]). The goat anti-rabbit and
anti-mouse IgGs conjugated to 12 nm and 18 nm colloi-
dal gold particles, respectively, were obtained from Jack-
son ImmunoResearch Laboratories. All other secondary
antibodies were from Sigma.
Cell culture, transfections, and (immuno)fluorescence 
microscopy
Primary hepatocytes from mouse embryos (13.5 days) of
Arf6+/+ and Arf6-/- littermates were isolated and cultivated
as described [31]. After 12 hours, the cells were fixed with
ice-cold paraformaldehyde (4% (w/v) in PBS), washed
with PBS, and stored until needed. Potorous tridactylis
(kangaroo rat) kidney (Ptk2) cells (a gift from Dr. M.
Mareel, University Hospital of Ghent, Belgium), allowing
for easier imaging given their flat profile [71], were cul-
tured in DMEM/F-12 medium supplemented with 10%
(v/v) fetal calf serum, 2 mM Glutamax (Invitrogen), an
antibiotic-antimycotic (100 μg/ml penicillin G, 100 μg/
ml streptomycin sulphate, 0.25 μg/ml amphotericin B)
mixture (Invitrogen), and 5 μg/ml Plasmocin (Amaxa) in
a humidified 37°C, 5% CO2 incubator, and transiently
transfected by using Lipofectamine Plus (Invitrogen). The
cells were fixed with paraformaldehyde (see above) 36
hours post-transfection. Processing of the cell samples for
(immuno)fluorescence microscopy was carried out as
described [72], and fluorescence was evaluated on a CellM
imaging station (Olympus) equipped with U-MNUA2, U-
MNIBA3, and U-MWIY2 fluorescence mirror units. The
Olympus image analysis and particle detection software
was used to determine the peroxisome density in Arf6+/+
and Arf6-/- cells.
Preparation of subcellular fractions and isolation of 
peroxisomal membranes
Rat liver was homogenized in 0.25 M sucrose, 5 mM
MOPS (pH 7.2), 1 mM EDTA (pH 7.2), 0.1% (v/v) etha-
nol, 1 mM dithiothreitol (DTT), and proteinase inhibitor
(PI) mixture (1 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1
μg/ml α2-macroglobulin, and 1 μg/ml chymostatin) and
fractionated by differential centrifugation into a nuclear,
heavy mitochondrial, light mitochondrial, microsomal,
and cytosolic fraction as described before [73]. Peroxi-
somes were purified from the light mitochondrial fraction
by (i) isopycnic centrifugation in an iso-osmotic self-gen-
erating Percoll gradient [74], (ii) centrifugation in a
Nycodenz step gradient [75], or (iii) centrifugation of per-
oxisome-enriched fractions from the Percoll gradient in a
Nycodenz step gradient [73]. In order to isolate peroxiso-
mal membranes, peroxisomal peak fractions in the
Nycodenz gradient were subjected twice to sonication in
10 mM pyrophosphate buffer (pH 9.0) and centrifuged at
100,000 × g for 1 hour [74]. To increase the purity of the
peroxisomal membranes, the membrane pellets were
resuspended in 1 ml of sucrose 52% (w/v) in 0.1 M
sodium carbonate (pH 11.5) and floated in an alkaline
linear sucrose gradient essentially as described previously
[76], with minor modifications. Briefly, resuspended
membrane pellets were carefully layered under 4 ml of a
continuous gradient (ranging from 12% to 44% (w/v)
sucrose in 0.1 M sodium carbonate (pH 11.5)). In order
to avoid the pelleting of protein aggregates at the bottom
of the centrifugation tubes, a 100 μl cushion of sucrose
80% (w/v) in 0.1 M sodium carbonate was layered under
the resuspended membrane pellets. The sucrose gradient
was centrifuged at 170,000 × g for 18 hours in a SW55Ti
rotor (Beckman Instruments) and fractionated into 200–
250 μl aliquots. The proteins present in each fraction were
precipitated with trichloroacetic acid and deoxycholate,
and processed for SDS-PAGE and immunoblotting.
Immunoelectron microscopy
Percoll, Nycodenz and Percoll/Nycodenz gradient frac-
tions enriched with peroxisomes were fixed in a freshly
prepared solution containing 0.25% (v/v) glutaralde-
hyde-containing, 5 mM MOPS (pH 7.2), 1 mM EDTA (pH
7.2), 1 mM DTT, 0.1% (v/v) ethanol, and PI mixture. In
order to prevent osmotic rupture of the organelles, the fix-
ative was supplemented with 0.25 M sucrose (Percoll frac-
tions) or Nycodenz (final density: 1.20 g/ml) (Nycodenz
and Percoll/Nycodenz fractions). Fixed samples contain-
ing 75 μg or 150 μg of protein were pelleted (11,000 × g,
2 min) and washed by resuspension and pelleting in (i)
homogenization buffer (see above), (ii) TBS buffer (0.1 M
Tris-HCl (pH 7.4), 9% (w/v) NaCl), and (iii) TBS buffer
supplemented with 0.1% (w/v) glycine. Non-specific pro-BMC Cell Biology 2009, 10:58 http://www.biomedcentral.com/1471-2121/10/58
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Effect of co-overexpression of Arf1 and Arf6 variants on peroxisomal and mitochondrial protein import in PtK2 cells Figure 7
Effect of co-overexpression of Arf1 and Arf6 variants on peroxisomal and mitochondrial protein import in 
PtK2 cells. (A) Ptk2 cells were transiently transfected with plasmids coding for no protein (/), Arf1WT-HA (1), Arf1T31N-HA 
(1-), or Arf1Q71L-HA (1+) and/or a bicistronic plasmid encoding EGFP-PTS1 together with no other protein (-), non-tagged 
Arf6WT (6), Arf6T27N (6-), or Arf6Q67L (6+). After 36 hours, the cells were fixed and processed for fluorescence analysis. The 
subcellular localization of EGFP-PTS1 was determined by its punctate (peroxisomal) or diffuse staining pattern in at least 250 
cells, and the results were quantified. (B) Representative images of the subcellular distribution pattern of EGFP-PTS1, 
HsPMP34-Myc-His, and HsLK2-Myc-His in Ptk2 cells co-overexpressing Arf1T31N and Arf6T27N. Note that the latter protein is 
encoded by the bicistronic expression vector coding for EGFP-PTS1, and a mislocalization of the reporter proteins is only 
observed in double-transfected cells. As (i) in mammalian cells the fluorescence intensity of EGFP-PTS1 is significantly higher 
upon mislocalization to the cytosol [77], and (ii) this increase may mask the (partial) association of this reporter protein with 
peroxisomes, insets are included in which the outlined regions are shown with moderately less intense green fluorescence sig-
nals. Scale bar: 20 μm.
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tein binding sites were blocked for 45 min in TBS buffer
supplemented with 1% (w/v) BSA, and the organelle
preparations were subsequently incubated with the pri-
mary antibodies (mouse 1D9 (1:10 – 1:500) or mouse
anti-Arf6 (1:50 – 1:100) and rabbit anti-Pex14p (1:20 –
1:1000) or rabbit anti-PMP70 (1:20 – 1:1000) diluted in
TBST (TBS buffer supplemented with 0.05% (v/v) Tween-
20)) overnight at 4°C. The next morning, the prepara-
tions were washed three times with TBS buffer, incubated
with the secondary antibodies (goat anti-rabbit (1:5 –
1:20) and anti-mouse IgGs (1:5 – 1:10) conjugated to 12
nm and 18 nm colloidal gold particles, respectively,
diluted in TBST) for two hours at 4°C, and washed three
times with TBS buffer (and pelleted for 2 min at decreas-
ing pelleting speeds: 11,000 × g, 5,000 × g, and 2,000 × g).
Negative controls were processed in parallel by addition
of TBST buffer instead of the primary antibodies. Hereaf-
ter, the immuno-treated organelle samples were fixed in
TBS buffer supplemented with 0.1 M cacodylate (pH 7.4)
and 1% (v/v) glutaraldehyde for 30 min, and subse-
quently washed with 0.1 M cacodylate (pH 7.4). After-
wards, the samples were post-fixed with aqueous
potassium ferricyanide-reduced osmium tetroxide (final
concentration: 1% (w/v) OsO4; 150 mg/ml K4 [Fe(CN)6])
for 45 min, shortly rinsed with Milli-Q water, and immo-
bilized on Formvar-coated 400 mesh nickel grids (see
below) or embedded in tepid agar-agar (7.5% (w/v) in
Milli-Q). The in agar-agar-embedded pellets were care-
fully cut into small blocks and dehydrated by passage
through graded series of ethanol (70% (v/v), 80% (v/v),
90% (v/v), and absolute), transferred to propylene oxide,
and embedded in Epoxy resin (Agar 100 Resin Kit, Agar
Scientific). The Epon blocks were trimmed and ultrathin
sections (75 nm and 300 nm) were put on a 200 mesh
copper/rhodium grid. The organelles were contrasted with
2% (w/v) uranyl acetate and Reynold's lead citrate for 2
min and 40 sec, respectively, and rinsed with Milli-Q
water. To immobilize immunostained or non-immunos-
tained glutaraldehyde-fixed organelle samples directly on
Formvar-coated 400 mesh nickel grids, the grids were first
incubated with a poly-L-lysine solution (0.01% (w/v)
poly-L-lysine, 0.625% (w/v) boric acid, 0.955% (w/v)
sodium tetraborate) for 45 min and subsequently incu-
bated on a drop of the organelle samples for another 45
min. Next, the grids containing immunostained samples
were put on a drop of TBS for 10 min, shortly rinsed with
the same buffer, and dried. The grids containing non-
immunostained organelle samples were washed for 15
min on a drop of TBS and 5 min on a drop of TBS supple-
mented with 0.1% (w/v) glycine, blocked for 45 min on a
drop TBS supplemented with 4% (w/v) BSA, and for one
hour incubated with primary and secondary antibodies
diluted in TBST supplemented with 0.1% (w/v) BSA. Each
antibody incubation was ended by washing the immobi-
lized organelles 12 times for 5 min on a drop of TBS. Neg-
ative controls were processed in parallel by addition of
TBST buffer instead of the primary antibodies. Finally, the
organelle samples were shortly rinsed with TBS, negatively
stained by incubating them for 3 min with 0.25% (w/v)
uranyl acetate, and dried on a filter paper. All samples
were examined with a LEO 906 electron microscope
(Zeiss).
Statistics
Statistical analyses were performed with SAS (Statistical
Analysis System) software. ANOVA (Analysis of Variance)
was used to determine the differences among independ-
ent groups of numerical values, and multiple compari-
sons with Tukey-Kramer adjustment were used to
determine which groups were significantly different from
the wild-type group. The significance level was chosen to
be 0.05.
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Phenotypic analysis of the oleate-grown Δarf1Δarf3 S. cerevisiae 
strain. Serial dilutions of wild-type (WT) yeast cells (strain BY4741) and 
yeast cells deficient in Arf1 (Δarf1), Arf3 (Δarf3), or Arf1 and Arf3 
(Δarf1Δarf3) expressing EGFP-PTS1 were spotted onto plates with oleate 
as a sole carbon source. The plates were subsequently incubated at 30°C 
for five days. (A) Oleate consumption was scored by halo formation. (B) 
The subcellular distribution pattern of EGFP-PTS1 was visualized by flu-
orescence microscopy. The scale bar represents 5 μm. (C) The number of 
peroxisomes per cell was counted in randomly selected cells. The mean 
number of peroxisomes per cell is indicated by an asterisk. At least 150 
oleate-grown cells were scored.
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